A bioreactor
is a vessel that has been constructed or manufactured for the production of a
wide range of biological products. A biochemical process is carried out in an
industrial bioreactor using microbes and animal cells, or biologically active
compounds derived from living cells. The most significant component in
bioprocessing is the bioreactor, which is cylindrical in shape and has a
capacity ranging from litres to cubic metres. Bioreactors are used in
fermentation processes such as wine and beer manufacture. Stainless steel is
used in bioreactors for large-scale manufacturing of medicinal goods. Small
glass bioreactors are utilised in biopharmaceutical firms for research and
development as well as scale-up activities. Disposable bioreactors, also known as
single-use bioreactors, are another form of bioreactor. They are designed to be
used only once. It's commonly utilised for prolonged study and production.
Batch, fed batch, and continuous stirred tank operations are all possible with
bioreactors.
Market Drivers
In terms of
manufacturing, quality control, and procurement, the efficiency of single-use
bioreactors has improved across the pharmaceutical industry. Single-use
bioreactors provide benefits such as uniformity in production, increased
manufacturing speed, lower operational costs, and shorter manufacturing time
for completed dosage forms, all of which contribute to the bioreactors
market's growth. According to the National Center for Biotechnology
Information (NCBI), single-use bioreactors have a 22 percent lower operational
cost per gramme of monoclonal antibody production (mAb) than conventional
systems, owing to decreased manpower, utilities, maintenance, and trash.
Market Regional Insights
Because of
the existence of significant biopharmaceutical manufacturing businesses, North
America is projected to hold a dominating position in the bioreactors market.
In the United States, biopharmaceutical companies including Gilead Science,
Inc., Amgen, and Biogen, Inc. are actively conducting research on innovative
treatments for the treatment of a variety of ailments. Oncology-related
medicines, such as monoclonal antibodies, necessitate the use of bioreactors on
a small and big scale for production purposes. Furthermore, according to the
National Center for Biotechnology Information (NCBI), single-use bioreactors
were used by 65.6 percent of clinical scale manufacturers and roughly 42
percent of commercial manufacturers in 2014 to optimise their bioprocessing.
Due to increased use of bioreactors in biopharmaceutical businesses, Europe is
likely to see considerable growth in the bioreactors market. According to the
Organization for Economic Co-operation and Development (OECD), around 1,700
biopharmaceutical enterprises using bioreactors were based in Europe in 2015.
Comments
Post a Comment